Table 5.
Multivariable Cox analyses of patient mortality and death-censored allograft failure
| Mortality | Allograft failure | ||||||
|---|---|---|---|---|---|---|---|
| HR | CI | p-value | HR | CI | p-value | ||
| Recipient of: | |||||||
| DIRVI kidney | Reference | Reference | |||||
| SCD kidney | 0.71 | 0.58–0.87 | <0.01 | 1.09 | 0.78–1.51 | 0.62 | |
| ECD kidney | 0.98 | 0.83–1.17 | 0.83 | 1.93 | 1.33–2.81 | <0.01 | |
| DCD kidney | 0.67 | 0.54–0.83 | <0.01 | 1.19 | 0.82–1.73 | 0.36 | |
| Recipient age (years) | |||||||
| Age<40 | Reference | Reference | |||||
| 40≤age<50 | 1.34 | 1.16–1.55 | <0.01 | 0.83 | 0.70–0.98 | 0.03 | |
| 50≤age<60 | 2.44 | 2.12–2.81 | <0.01 | 0.76 | 0.64–0.89 | <0.01 | |
| 60≤age<70 | 3.23 | 2.65–3.92 | <0.01 | 0.79 | 0.64–0.98 | 0.03 | |
| Age≥70 | 5.69 | 4.41–7.35 | <0.01 | 0.60 | 0.46–0.78 | <0.01 | |
| Recipient black race | 0.94 | 0.84–1.04 | 0.21 | 1.56 | 1.36–1.78 | <0.01 | |
| Recipient male | 1.13 | 1.05–1.23 | <0.01 | 1.06 | 0.96–1.16 | 0.24 | |
| Recipient prior kidney transplant | 1.20 | 0.99–1.45 | 0.06 | 1.29 | 1.12–1.47 | <0.01 | |
| Recipient on dialysis | 1.30 | 1.09–1.56 | <0.01 | 1.16 | 0.96–1.42 | 0.13 | |
| Recipient diabetes | 1.74 | 1.54–1.96 | <0.01 | 0.98 | 0.88–1.08 | 0.67 | |
| Recipient hepatitis C sero-positive | 1.63 | 1.37–1.94 | <0.01 | 1.40 | 1.22–1.61 | <0.01 | |
| Recipient HIV sero-positive | 1.24 | 0.69–2.21 | 0.46 | 1.39 | 0.95–2.03 | 0.09 | |
| Recipient high PRA* | 1.53 | 1.25–1.88 | <0.01 | 1.30 | 1.08–1.55 | <0.01 | |
| CMV positive recipient | 1.01 | 0.91–1.11 | 0.87 | 0.95 | 0.87–1.03 | 0.20 | |
| CMV positive donor | 1.09 | 1.00–1.20 | 0.05 | 1.15 | 1.07–1.24 | <0.01 | |
| Wait-list time>1000 days | 1.13 | 0.97–1.32 | 0.11 | 0.99 | 0.89–1.11 | 0.89 | |
| Dual organ transplant | 1.16 | 0.89–1.50 | 0.28 | 0.72 | 0.57–0.91 | <0.01 | |
| Donor black race | 1.12 | 0.96–1.29 | 0.15 | 1.10 | 0.95–1.29 | 0.21 | |
| Donor male | 0.92 | 0.84–1.01 | 0.07 | 0.95 | 0.84–1.06 | 0.36 | |
| Allograft cold ischemia (hours) | |||||||
| <12 | Reference | Reference | |||||
| 12≤time<24 | 1.04 | 0.91–1.18 | 0.59 | 1.09 | 0.94–1.26 | 0.28 | |
| ≥24 | 0.96 | 0.81–1.14 | 0.63 | 1.12 | 0.91–1.37 | 0.30 | |
| Non-local transplant | 0.93 | 0.76–1.14 | 0.50 | 1.00 | 0.81–1.23 | 0.99 | |
| Zero mismatch | 0.89 | 0.73–1.07 | 0.22 | 0.71 | 0.57–0.89 | <0.01 | |
| Steroid induction | 1.08 | 0.96–1.20 | 0.19 | 1.12 | 0.96–1.30 | 0.17 | |
| Antibody induction | Reference | Reference | |||||
| Lymphocyte depleting | 1.08 | 0.96–1.22 | 0.22 | 1.09 | 0.95–1.23 | 0.21 | |
| Non- Lymphocyte depleting | 1.14 | 0.97–1.33 | 0.11 | 1.08 | 0.92–1.27 | 0.37 | |
| Initial immuno-suppression | |||||||
| Tacrolimus based | Reference | Reference | |||||
| Cyclosporine based | 1.19 | 0.98–1.44 | 0.09 | 1.12 | 0.98–1.49 | 0.08 | |
| Rapamycin based | 1.27 | 1.05–1.52 | 0.01 | 1.54 | 1.22–1.93 | <0.01 | |
| Other | 1.92 | 1.59–2.32 | <0.01 | 2.81 | 2.39–3.31 | <0.01 | |
| Transplant era | |||||||
| 1996 – 1998 | Reference | Reference | |||||
| 1999 – 2002 | 0.94 | 0.79–1.12 | 0.48 | 1.09 | 0.98–1.23 | 0.12 | |
| 2003 – 2006 | 0.87 | 0.73–1.05 | 0.15 | 1.05 | 0.83–1.34 | 0.68 | |
*
Defined as ≥80% peak panel reactive antigen
DIRVI: donor at increased risk for viral infection according to the Centers for Disease Control categorization; SCD: Standard criteria donor; ECD: Expanded criteria donor; DCD: donation after cardiac death; HIV: human immunodeficiency virus